United States

NIH awards $15.6 million for pulmonary research program

Thursday, October 16, 2014 02:29 PM

The NIH has awarded up to $15.6 million in grants over five years to the University of North Carolina, Chapel Hill (UNC-CH) and the University of Colorado, Denver (UCD) to conduct research with mucolytic agents discovered by Parion Sciences, a Durham, N.C.-based company focused on pulmonary and ocular diseases, and to enable Investigational New Drug applications for Parion's molecules.

More... »


Novartis publishes CTL019 data for acute lymphoblastic leukemia

Thursday, October 16, 2014 11:55 AM

Novartis and the University of Pennsylvania's Perelman School of Medicine have announced preliminary results from two pilot clinical trials published in The New England Journal of Medicine (NEJM) evaluating the efficacy and safety of CTL019 in patients with relapsed/refractory acute lymphoblastic leukemia (r/r ALL). The studies, conducted by Penn, demonstrated that 27 of 30 pediatric and adult patients, or 90%, experienced complete remissions with the investigational chimeric antigen receptor (CAR) therapy CTL019.

More... »


FDA approves Ofev to treat idiopathic pulmonary fibrosis

Thursday, October 16, 2014 11:49 AM

The FDA has approved Ofev (nintedanib) for the treatment of idiopathic pulmonary fibrosis (IPF).

More... »

Celerion joins Cardiac Safety Research Consortium

Thursday, October 16, 2014 07:00 AM

Celerion, a Lincoln, Neb.-based provider of cardiovascular safety services in early clinical research, has become a member of the Cardiac Safety Research Consortium (CSRC). Celerion will engage with other thought leaders on key issues that impact cardiovascular safety, including discussions of alternative approaches to ICH E14 to assess arrhythmia liability in early drug development.

More... »

PhotoxAir reduces airborne bacteria in clinical trials

Thursday, October 9, 2014 11:54 AM

Wake Forest Baptist Medical Center, a North Carolina-based medical center, has announced that studies have conclusively demonstrated that the PhotoxAir purification system significantly reduced airborne bacteria in clinical trials conducted in an emergency department setting.

More... »

Bristol-Myers Squibb withdraws NDA with FDA for asunaprevir

Thursday, October 9, 2014 11:51 AM

Given the rapidly evolving hepatitis C (HCV) treatment landscape in the U.S., Bristol-Myers Squibb has decided that it will not pursue FDA approval of the dual regimen of daclatasvir and asunaprevir for the treatment of HCV genotype 1b patients in the U.S. and has therefore withdrawn its new drug application (NDA) for asunaprevir, an NS3/4A protease inhibitor. The company will continue to pursue FDA approval of daclatasvir, a potent, pan-genotypic NS5A complex inhibitor (in vitro), which currently is being investigated globally in multiple treatment regimens for HCV patients with high unmet need.

More... »

Chimerix receives Emergency Investigational NDA for Ebola

Thursday, October 9, 2014 11:45 AM

Chimerix, a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, has announced that brincidofovir has been provided for potential use in patients with Ebola virus disease. These requests were made by treating physicians. Emergency Investigational New Drug Applications (EIND) were granted by the FDA.

More... »

Quest Diagnostics names Franklin R. Cockerill VP, chief laboratory officer

Thursday, October 9, 2014 11:10 AM

Quest Diagnostics, a provider of diagnostic information services, has announced that Franklin R. Cockerill, III, M.D., has joined the company as vice president and chief laboratory officer, effective Oct. 1.

More... »

Second Genome, Mayo Clinic collaborate to develop microbiome therapeutics

Thursday, October 9, 2014 09:00 AM

Second Genome, a South San Francisco, Calif.-based developer of novel medicines through innovative microbiome science, has entered into an extensive partnership with the Minnesota-based Mayo Clinic Center for Individualized Medicine to support the development of therapeutic products for multiple disease indications, starting with inflammatory bowel disease, metabolic disorders and colorectal cancer.

More... »

NanoString, Brigham and Women's Hospital collaborate

Thursday, October 9, 2014 08:30 AM

NanoString Technologies, a Seattle, Wash.-based provider of life science tools for translational research and molecular diagnostic products, has signed a multi-year, multi-investigator research collaboration with Harvard-affiliated, Boston, Mass.-based Brigham and Women's Hospital (BWH) to accelerate the translation of genomic biomarker discoveries into clinical cancer diagnostics. Using NanoString's Elements reagents, assays will be developed to detect gene expression, copy number variations and fusions from a diverse range of tumor samples.

More... »

`

CWWeekly

July 27

AB Science warned about putting study volunteers in danger

FDA, Google unite to detect search-data adverse events

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

July

Integrated research partnerships build momentum
Research function provides infrastructure, leverages large pool of health systems' patients and data

'Right to Try' laws challenge clinical trial process
20 states pass, 20 more pending allowing access to study drugs without FDA and IRB approval

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

June

TransCelerate Biopharma turns three
High-profile consortium has made inroads fixing wasteful practices, but it still has more work ahead

Pharma industry improves its tarnished reputation
Delivering innovation, social responsibility will help rebuild trust

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs